Masaji Okada

Summary

Affiliation: National Hospital Organization
Country: Japan

Publications

  1. ncbi request reprint Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model
    Yoko Kita
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Sakai, Osaka 591 8555, Japan
    Vaccine 23:2132-5. 2005
  2. ncbi request reprint [Immunity against Mycobacterium tuberculosis (introduction)]
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku, Sakai shi, Osaka 591 8555, Japan
    Kekkaku 85:501-8. 2010
  3. ncbi request reprint Tuberculosis vaccine development: The development of novel (preclinical) DNA vaccine
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, Kita ku, Sakai City, Osaka, Japan
    Hum Vaccin 6:297-308. 2010
  4. doi request reprint Novel prophylactic and therapeutic vaccine against tuberculosis
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591 8555, Japan
    Vaccine 27:3267-70. 2009
  5. ncbi request reprint [Anti-tuberculosis immunity by cytotoxic T cells * granulysin and the development of novel vaccines (HSP-65 DNA+IL-12 DNA)]
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku, Sakai shi, Osaka 591 8555, Japan
    Kekkaku 85:531-8. 2010
  6. ncbi request reprint Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591 8555, Japan
    Vaccine 25:3038-40. 2007
  7. ncbi request reprint Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591 8555, Japan
    Vaccine 25:2990-3. 2007
  8. ncbi request reprint [Novel vaccines against M. tuberculosis]
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku, Sakai shi, Osaka 591 8555, Japan
    Kekkaku 81:745-51. 2006
  9. pmc Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis
    Masaji Okada
    Clinical Research Center, National Hospital Organization, Kinki chuo Chest Medical Center, Kitaku, Sakai, Osaka, Japan
    Clin Dev Immunol 2011:549281. 2011
  10. doi request reprint Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, Kitaku, Sakai, Osaka, Japan
    Hum Vaccin 7:60-7. 2011

Collaborators

Detail Information

Publications35

  1. ncbi request reprint Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model
    Yoko Kita
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Sakai, Osaka 591 8555, Japan
    Vaccine 23:2132-5. 2005
    ..Most importantly, HSP65+IL-12/HVJ resulted in an increased survival for over a year. This is the first report of successful DNA vaccination and recombinant BCG vaccination against M. tuberculosis in the monkey model...
  2. ncbi request reprint [Immunity against Mycobacterium tuberculosis (introduction)]
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku, Sakai shi, Osaka 591 8555, Japan
    Kekkaku 85:501-8. 2010
    ..The development novel vaccine (HSP65+IL-12 DNA vaccine), (5) The mechanism of protection against TB, in this mini-review series...
  3. ncbi request reprint Tuberculosis vaccine development: The development of novel (preclinical) DNA vaccine
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, Kita ku, Sakai City, Osaka, Japan
    Hum Vaccin 6:297-308. 2010
    ....
  4. doi request reprint Novel prophylactic and therapeutic vaccine against tuberculosis
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591 8555, Japan
    Vaccine 27:3267-70. 2009
    ..These data indicate that our novel DNA vaccine might be useful against Mycobacterium tuberculosis including XDR-TB and MDR-TB for human therapeutic clinical trials...
  5. ncbi request reprint [Anti-tuberculosis immunity by cytotoxic T cells * granulysin and the development of novel vaccines (HSP-65 DNA+IL-12 DNA)]
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku, Sakai shi, Osaka 591 8555, Japan
    Kekkaku 85:531-8. 2010
    ....
  6. ncbi request reprint Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591 8555, Japan
    Vaccine 25:3038-40. 2007
    ..These results show that these vaccines can induce virus-specific immune responses and should provide a useful tool for development of protective and therapeutic vaccines...
  7. ncbi request reprint Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591 8555, Japan
    Vaccine 25:2990-3. 2007
    ..These data indicate that our novel DNA vaccine might be useful against Mycobacterium tuberculosis for human clinical trials...
  8. ncbi request reprint [Novel vaccines against M. tuberculosis]
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku, Sakai shi, Osaka 591 8555, Japan
    Kekkaku 81:745-51. 2006
    ....
  9. pmc Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis
    Masaji Okada
    Clinical Research Center, National Hospital Organization, Kinki chuo Chest Medical Center, Kitaku, Sakai, Osaka, Japan
    Clin Dev Immunol 2011:549281. 2011
    ..The only tuberculosis (TB) vaccine currently available is bacillus Calmette-Guérin (BCG), although it has no efficacy in adults. Therefore, the development of a novel vaccine against TB for adults is desired...
  10. doi request reprint Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, Kitaku, Sakai, Osaka, Japan
    Hum Vaccin 7:60-7. 2011
    ..Multi-drug resistant (MDR) Mycobacterium Tuberculosis (M.TB) is a big problem in the world. We have developed novel TB therapeutic vaccines...
  11. ncbi request reprint [Frontier of mycobacterium research--host vs. mycobacterium]
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, Sakai shi, Osaka, Japan
    Kekkaku 80:613-29. 2005
    ..In Japan, Dr. Masaji Okada (National Hospital Organization Kinki-Chuo Chest Medical Center) has been engaged actively in the development ..
  12. pmc Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-α antibody in mice
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, Osaka 591 8555, Japan
    Clin Dev Immunol 2011:404929. 2011
    ..Conclusion. IL-6R blockade promotes the progression of TB infection in mice far less than TNF-α blockade...
  13. ncbi request reprint The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Sakai, Osaka 591 8555, Japan
    Vaccine 23:2269-72. 2005
    ..As expected, virus-specific CTL responses and T cell proliferation were induced from human T cells. SARS-N and SARS-M DNA vaccines and SCID-PBL/hu mouse model will be important in the development of protective vaccines...
  14. ncbi request reprint Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models
    Yoko Kita
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, Kitaku, Sakai, Osaka, Japan
    Hum Vaccin 7:108-14. 2011
    ..Therefore, novel TB vaccines were established by using three kinds of animal models (cynomolgus monkey model which is the best animal model of human TB, IL-2R knock out SCID mice as a human immune model, and granulysin transgenic mouse)...
  15. ncbi request reprint Development of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse models
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, Sakai, Osaka, Japan
    Adv Exp Med Biol 581:561-6. 2006
    ..These vaccines are expected to induce immune responses specific for SARS CoV in human and should provide useful tool for development of protective vaccines...
  16. doi request reprint Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay
    Shiomi Yoshida
    Clinical Research Center, National Hospital Organization, Kinki chuo Chest Medical Center, 1180 Nagasone cho, Sakai, 591 8555, Japan
    J Infect Chemother 16:360-3. 2010
    ..Our results indicated that rifabutin continues to remain active against MDR-TB strains harboring certain genetic alterations and also that the LiPA might be useful in identifying MDR-TB strains susceptible to rifabutin...
  17. ncbi request reprint [Evaluation of the INNO-LiPA MYCOBACTERIA v2 for mycobacterial identification]
    Shiomi Yoshida
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, Osaka, Japan
    Kekkaku 84:15-21. 2009
    ..Evaluation of the INNO-LiPA MYCOBACTERIA v2 (the INNO-LiPA assay) for mycobacterial identification...
  18. ncbi request reprint [Molecular epidemiology of rifampicin mono-resistant Mycobacterium tuberculosis]
    Shiomi Yoshida
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku, Sakai shi, Osaka 591 8555 Japan
    Kekkaku 87:41-5. 2012
    ..We aimed to investigate the prevalence and possible transmission routes of rifampicin (RFP) mono-resistant Mycobacterium tuberculosis strains...
  19. ncbi request reprint [Detection of molecular epidemiology of Mycobacterium gordonae isolates]
    Shiomi Yoshida
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, Osaka, Japan
    Kekkaku 85:609-14. 2010
    ..To analyze the molecular epidemiology of Mycobacterium gordonae strains from patients and environments in the hospital...
  20. ncbi request reprint [The development of novel vaccines against tuberculosis]
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center
    Nihon Rinsho Meneki Gakkai Kaishi 31:356-68. 2008
    ..In contrast, 33% of monkeys from BCG Tokyo alone group were alive (33% survival). These data indicate that our novel DNA vaccine might be useful against Mycobacterium tuberculosis for human clinical trials...
  21. ncbi request reprint [Molecular epidemiology of Mycobacterium tuberculosis--comparison between multidrug-resistant strains and susceptible strains]
    Shiomi Yoshida
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku, Sakai shi, Osaka 591 8555, Japan
    Kekkaku 82:531-8. 2007
    ..Comparing multidrug-resistant M. tuberculosis strains with susceptible strains by molecular epidemiological methods...
  22. ncbi request reprint Neuritogenic effects of T cell-derived IL-3 on mouse splenic sympathetic neurons in vivo
    Yukiko Kannan-Hayashi
    Laboratory of Integrative Physiology, Division of Veterinary Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Sakai, Osaka, Japan
    J Immunol 180:4227-34. 2008
    ..On the contrary, NK cells may exert an inhibitory effect on the sympathetic innervation...
  23. ncbi request reprint [Recent progress in mycobacteriology]
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, Japan
    Kekkaku 82:783-99. 2007
    ..5. The development of novel vaccines against M. tuberculosis: Masaji OKADA (Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center) We have developed a ..
  24. doi request reprint Further isolation of Mycobacterium abscessus subsp. abscessus and subsp. bolletii in different regions of Japan and susceptibility of these isolates to antimicrobial agents
    Shiomi Yoshida
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku Sakai, Osaka 591 8555, Japan Electronic address
    Int J Antimicrob Agents 42:226-31. 2013
    ..Strains with acquired resistance to clarithromycin and mutation in rrl consisted of two M. bolletii (one 'M. massiliense' and one 'M. bolletii') and two M. abscessus T28 sequevar. ..
  25. ncbi request reprint [Comparative evaluation of acid-fast staining for the detection of Mycobacterium fortuitum--clinical performance of fluorescent and Ziehl-Neelsen staining]
    Shiomi Yoshida
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku, Sakai shi, Osaka 591 8555, Japan
    Kekkaku 88:461-7. 2013
    ....
  26. ncbi request reprint [Evaluation of the discrepant Mycobacterium tuberculosis strains between any ordinary susceptibility testing and rpoB gene analysis by the line probe assay]
    Shiomi Yoshida
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku, Sakai shi, Osaka 591 8555, Japan
    Kekkaku 83:577-83. 2008
    ..Evaluation of rifampicin-resistance by the line probe assay, for rifampicin-susceptible Mycobacterium tuberculosis strains which were classified as rifampicin-resistant by the phenotypic drug susceptibility testings...
  27. ncbi request reprint Immunization with dendritic cells retrovirally transduced with mycobacterial antigen 85A gene elicits the specific cellular immunity including cytotoxic T-lymphocyte activity specific to an epitope on antigen 85A
    Hideki Nakano
    Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1 20 1 Handa yama, Hamamatsu 431 3192, and Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, Osaka, Japan
    Vaccine 24:2110-9. 2006
    ..This eliciting cellular immunity led to protection against wasting disease due to M. tuberculosis infection and induction of moderate bacterial clearance...
  28. ncbi request reprint [Analysis of the clinical features of pulmonary disease caused by Mycobacterium szulgai]
    Yumiko Sasaki
    Department of Internal Medicine, National Hospital Organization Kinki chuo Chest Medical Center, Osaka, Japan
    Kekkaku 87:391-6. 2012
    ..In addition, drug susceptibility testing of the causative isolates was performed with several antibiotics, including clarithromycin (CAM) and rifampicin (RFP), using BrothMIC NTM...
  29. ncbi request reprint [An adolescent case of pulmonary MAC infection, found 3 years later from bone marrow transplantation for myelodysplastic syndrome]
    Seijiro Minamoto
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku, Sakai shi, Osaka 591 8555, Japan
    Kekkaku 83:585-90. 2008
    ....
  30. ncbi request reprint [Detection of rpoB mutations in rifampicin-resistant Mycobacterium kansasii]
    Shiomi Yoshida
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku, Sakai shi, Osaka 591 8555 Japan
    Kekkaku 81:475-9. 2006
    ..To detect rifampicin-resistant mutations in Mycobacterium kansasii (M. kansasii)...
  31. ncbi request reprint [Molecular epidemiological analysis of Mycobacterium kansasii isolates]
    Shiomi Yoshida
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone cho, Kita ku, Sakai shi, Osaka 591 8555 Japan
    Kekkaku 82:103-10. 2007
    ..To make molecular epidemiological analysis of Mycobacterium kansasii (M. kansasii) isolates...
  32. pmc Induction of protective cellular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51
    Keita Miki
    Department of Microbiology and Immunology, Hamamatsu University School of Medicine, Handayama, Hamamatsu, Japan
    Infect Immun 72:2014-21. 2004
    ..Notably, this is the first report to show that MPB/MPT51 is a major protective antigen in addition to Ag85A and Ag85B, which have been reported to be major mycobacterial protective antigens...
  33. ncbi request reprint Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens
    Toru Mori
    Research Institute of Tuberculosis, 3 1 24 Matsuyama, Kiyose, Tokyo 204 8533, Japan
    Am J Respir Crit Care Med 170:59-64. 2004
    ..tuberculosis infection was 89.0%. The results demonstrate that the whole blood IFN-gamma assay using CFP-10 and ESAT-6 was highly specific and sensitive for M. tuberculosis infection and was unaffected by BCG vaccination status...
  34. ncbi request reprint DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation
    Shigeto Yoshida
    Division of Medical Zoology, Department of Infection and Immunity, Jichi Medical School, Tochigi 329 0498, Japan
    Vaccine 24:1191-204. 2006
    ..tuberculosis. These results suggest that Hsp65 + IL-12/HVJ could be a promising candidate for a new tuberculosis DNA vaccine, which is superior to BCG vaccine...
  35. ncbi request reprint Baculovirus virions displaying Plasmodium berghei circumsporozoite protein protect mice against malaria sporozoite infection
    Shigeto Yoshida
    Division of Medical Zoology, Department of Infection and Immunity, Jichi Medical School, 329 0498, Tochigi, Japan
    Virology 316:161-70. 2003
    ..These data demonstrate that AcNPV-CSPsurf displays sporozoite-like PbCSP on the virion surface and possesses dual potentials as a malaria vaccine candidate and a liver-directed gene delivery vehicle...